MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP: PMBHF )

N/A UNCHANGED
Last Price Updated: 9:46 AM EST, Jan 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.1200
Today's Range N/A - N/A
52wk Range 0.0316 - 0.1374
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.  
Via Benzinga
Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More
Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024.  
Via Benzinga

Performance

More News

Read More
PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance
From PharmAla Biotech
Via GlobeNewswire
Canada To Australia: New MDMA & Psilocybin Shipment On Its Way For Legal Therapeutic Market
Via Benzinga
PharmAla Begins Trading on OTCQB
From PharmAla Biotech
Via GlobeNewswire
Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More
Via Benzinga
Psyched: Portugal Decriminalizes Synthetic Drugs, Anorexia And Psilocybin, LSD Microdosing, California & More
Via Benzinga
PharmAla Files IP Protection For Novel MDXX Molecule: Viability As Autism Spectrum Treatment
Via Benzinga
PharmAla Files Patent for Novel MDXX Molecule PharmAla-1
From PharmAla Biotech
Via GlobeNewswire
Cybin, Bright Minds And PharmAla: A Short Recap On Progress Within Clinical Trials
Via Benzinga
Psyched: Australia's Innovative Program, Congressional Amendments, Therapy Reimbursement And More
Via Benzinga
PharmAla's Australian JV Cortexa Orders First Commercial MDMA & Psilocybin Shipment
Via Benzinga
Life Science Investor Forum: Presentations Now Available for Online Viewing
From Virtual Investor Conferences
Via GlobeNewswire
Life Science Investor Forum Agenda Announced for June 22nd
From Virtual Investor Conferences
Via GlobeNewswire
MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University
Via Benzinga
Canadian Financing: PharmAla Biotech Offers Non-Brokered Private Placement Up To $3.76M
Via Benzinga
Promising Milestone: FDA Approves California-Based Trial Assessing MDMA For Schizophrenia
Via Benzinga
USFDA Approves LaNeo MDMA for Clinical Trial Use in the United States
From PharmAla Biotech
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
TOP
Email a Story